7 Analysts Assess Alkermes: What You Need To Know
Throughout the last three months, 7 analysts have evaluated Alkermes (NASDAQ:ALKS), offering a diverse set of opinions from ...
Alkermes Buy Rating Affirmed on Strong Commercial Performance and Promising Drug Pipeline
Goldman Sachs analyst Chris Shibutani maintained a Buy rating on Alkermes (ALKS – Research Report) today and set a price target of ...
Alkermes: Q1 Earnings Snapshot
DUBLIN — DUBLIN — Alkermes PLC (ALKS) on Wednesday reported first-quarter net income of $36.8 million, after reporting a loss in the same period a year earlier. The Dublin-based company said it had ...
Alkermes plc Reports First Quarter 2024 Financial Results
"The first quarter of 2024 marks our first full quarter as a profitable, pure-play neuroscience company. During the quarter, we continued to advance our strategic priorities acros ...
Yahoo Finance8d
Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates
Alkermes plc ALKS reported adjusted earnings from continuing operations of 44 cents per share for first-quarter 2024, which ...
SFGate10d
Alkermes: Q1 Earnings Snapshot
DUBLIN (AP) — DUBLIN (AP) — Alkermes PLC (ALKS) on Wednesday reported first-quarter net income of $36.8 million, after reporting a loss in the same period a year earlier. The Dublin-based ...
Nasdaq9d
Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates
Alkermes plc ALKS reported adjusted earnings from continuing operations of 44 cents per share for first-quarter 2024, which missed the Zacks Consensus Estimate of 59 cents. The company had ...